Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND: Panitumumab + FOLFIRI in second-line RAS wild-type mCRC
NCT03751176Phase 2Unknown
- Sponsor
- GEMCAD
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in colorectal cancer (metastatic) (mCRC), sponsored by GEMCAD. Status: unknown.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03751176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751176.